Imperagen 🇬🇧
Imperagen specializes in enzyme engineering, combining quantum physics-based simulations with automated testing to optimize enzyme performance.
About Imperagen
Imperagen specializes in enzyme engineering, utilizing a closed-loop system that combines quantum physics-based simulations with high-capacity automated testing to optimize enzyme variants for various industrial applications. Their approach leverages AI-driven selection and continuous feedback loops to refine models and enhance prediction accuracy, significantly accelerating the development of production-ready enzymes.
Imperagen is a UK-based company founded in 2021, now around 16 people. It has raised $11M in disclosed funding. FundFinder classes it as DeepTech & Space.
Founded by Tim Eyes (Director of Programs, Co-Founder; repeat founder; previously Innovate UK, Novartis; University of Manchester), Andrew Almond (Founder and CIO; repeat founder; previously C4X Discovery Ltd; University of Manchester).
Its investors also appear on FundFinder's most-active lists for Seed · Generalist (110 funds), Seed · AI (93 funds), Seed · Healthcare & Wellbeing (87 funds).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Seed · May 2026
Praetura Ventures- Praetura Ventures — Praetura have been supporting SMEs since 2011, raising capital and investing in the early stages of business life cycles. · cheques £1M – £3.5M